| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Vir Biotechnology (NASDAQ:VIR) reported its Q4 earnings results on Thursday, February 22, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Vir Biotechnology beat estimated earnings by 14.85%, reporting an EPS of $-0.86 versus an estimate of $-1.01.
Revenue was down $32.62 million from the same period last year.
Last quarter the company missed on EPS by $0.01 which was followed by a 6.96% increase in the share price the next day.
Here's a look at Vir Biotechnology's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.21 | -1.20 | -0.87 | -0.39 |
| EPS Actual | -1.22 | -1.45 | -1.06 | -0.76 |
| Revenue Estimate | 10.24M | 25.89M | 51.53M | 97.30M |
| Revenue Actual | 2.64M | 3.80M | 62.96M | 49.41M |
To track all earnings releases for Vir Biotechnology visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VIR
